Bio-Imaging Technologies ist profitabel! EPS 0,07 - 500 Beiträge pro Seite
eröffnet am 07.11.01 16:46:44 von
neuester Beitrag 08.11.01 18:31:00 von
neuester Beitrag 08.11.01 18:31:00 von
Beiträge: 7
ID: 501.027
ID: 501.027
Aufrufe heute: 0
Gesamt: 183
Gesamt: 183
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 32 Minuten | 3088 | |
vor 33 Minuten | 2516 | |
vor 30 Minuten | 1431 | |
vor 43 Minuten | 961 | |
vor 49 Minuten | 957 | |
gestern 21:04 | 910 | |
heute 06:53 | 769 | |
vor 25 Minuten | 601 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.282,87 | +0,36 | 289 | |||
2. | 4. | 1,1200 | -12,50 | 76 | |||
3. | 3. | 171,64 | +0,02 | 75 | |||
4. | 2. | 10,320 | -2,46 | 68 | |||
5. | 6. | 7,0280 | +1,56 | 38 | |||
6. | 13. | 0,1995 | +3,64 | 36 | |||
7. | 8. | 6,8220 | +0,12 | 35 | |||
8. | 5. | 86,40 | -0,35 | 34 |
NEWTOWN, Pa., Nov. 7 /PRNewswire/ -- Bio-Imaging Technologies, Inc. (OTC Bulletin Board: BITI) ("Bio-Imaging") today released results for the year ended September 30, 2001. Net income for the year ended September 30, 2001 was approximately $577,000, or $0.07 per diluted share, on revenues of approximately $8,755,000. This result compares to a net loss of approximately $692,000, or $(0.09) per diluted share, on revenues of approximately $5,772,000 for the year ended September 30, 2000.
Commenting on the results, Mark L. Weinstein, president and chief executive officer of Bio-Imaging stated, "We are very pleased to report revenue increases of approximately 52% from our last fiscal year. This factor combined with our continued profitability and increasing contracted/committed backlog shows that we are being successful in the marketplace. Our contracted/committed backlog as of October 31, 2001 is $28.6M which is an increase of 36% over September 30, 2000. In addition to these achievements, we are pleased that the number of clients that we worked with in Fiscal 2001 has increased by 26% over last year (42 to 53) and the number of projects has increased by 21% (91 to 111).
"On October 29, 2001, we announced the acquisition of the Intelligent Imaging business of Quintiles Transnational Corporation. The addition of Intelligent Imaging`s experienced personnel, excellent client relationships and contracted/ committee backlog will help us to continue our growth."
Bio-Imaging Technologies, Inc. is a pharmaceutical contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its U.S. Core Labs (Newtown and Plymouth Meeting, PA), European Core Lab (Leiden, The Netherlands) and U.S. Business Offices (New Jersey, Massachusetts and California).
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company`s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the integration of the Intelligent Imaging business into the Company`s operations, the timing of projects due to the variability in size, scope and duration of projects, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company`s control. The factors discussed herein and expressed from time to time in the Company`s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances
http://www.newsalert.com/bin/story?StoryId=Co:I_0bWbueHxmde4…
morchel
http://www.zockstocks.com
Commenting on the results, Mark L. Weinstein, president and chief executive officer of Bio-Imaging stated, "We are very pleased to report revenue increases of approximately 52% from our last fiscal year. This factor combined with our continued profitability and increasing contracted/committed backlog shows that we are being successful in the marketplace. Our contracted/committed backlog as of October 31, 2001 is $28.6M which is an increase of 36% over September 30, 2000. In addition to these achievements, we are pleased that the number of clients that we worked with in Fiscal 2001 has increased by 26% over last year (42 to 53) and the number of projects has increased by 21% (91 to 111).
"On October 29, 2001, we announced the acquisition of the Intelligent Imaging business of Quintiles Transnational Corporation. The addition of Intelligent Imaging`s experienced personnel, excellent client relationships and contracted/ committee backlog will help us to continue our growth."
Bio-Imaging Technologies, Inc. is a pharmaceutical contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its U.S. Core Labs (Newtown and Plymouth Meeting, PA), European Core Lab (Leiden, The Netherlands) and U.S. Business Offices (New Jersey, Massachusetts and California).
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company`s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the integration of the Intelligent Imaging business into the Company`s operations, the timing of projects due to the variability in size, scope and duration of projects, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company`s control. The factors discussed herein and expressed from time to time in the Company`s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances
http://www.newsalert.com/bin/story?StoryId=Co:I_0bWbueHxmde4…
morchel
http://www.zockstocks.com
Hallo Morchel,
hast du WKN parrat?
Danke
I F B
hast du WKN parrat?
Danke
I F B
Sorry!
morchel
morchel
morchel die WKN stand 8 min. nach seiner Frage in deinem
WKN Thread.
Wenn ihr beim traden auch so schnell seid .....
Ich hab jedenfalls Spaß satt.
miura
Sakrament!
morchel
morchel
Danke an alle für den schnellen Service.
Was haltet ihr von BITI?
Meldet euch mal.
Volumen hat auch angezogen.
Gruß
I F B
Was haltet ihr von BITI?
Meldet euch mal.
Volumen hat auch angezogen.
Gruß
I F B
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
288 | ||
75 | ||
71 | ||
70 | ||
39 | ||
35 | ||
32 | ||
32 | ||
27 | ||
27 |
Wertpapier | Beiträge | |
---|---|---|
27 | ||
26 | ||
22 | ||
22 | ||
21 | ||
20 | ||
20 | ||
19 | ||
17 | ||
17 |